<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32929655</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-4978</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Molecular biology reports</Title><ISOAbbreviation>Mol Biol Rep</ISOAbbreviation></Journal><ArticleTitle>Inositol hexakisphosphate kinase 2 promotes cell death of anterior horn cells in the spinal cord of patients with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>6479</StartPage><EndPage>6485</EndPage><MedlinePgn>6479-6485</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11033-020-05688-w</ELocationID><Abstract><AbstractText>We have previously reported that inositol hexakisphosphate kinase (InsP<sub>6</sub>K)2 mediates cell death. InsP<sub>6</sub>K2 is abundantly expressed in anterior horn cells of the mammalian spinal cord. We investigated the role of InsP<sub>6</sub>K2 in spinal cords of patients with amyotrophic lateral sclerosis (ALS). Autopsy specimens of lumbar spinal cords from ten patients with sporadic ALS and five non-neurological disease patients (NNDPs) were obtained. We performed quantitative real-time PCR, immunostaining, and western blotting for InsP<sub>6</sub>K1, InsP<sub>6</sub>K2, InsP<sub>6</sub>K3, protein kinase B (Akt), casein kinase 2 (CK2), and 90-kDa heat-shock protein (HSP90). In contrast to InsP<sub>6</sub>K1 and InsP<sub>6</sub>K3 mRNA expression, InsP<sub>6</sub>K2 levels in anterior horn cells of the spinal cord were significantly increased in ALS patients compared to NNDPs. In ALS patients, InsP<sub>6</sub>K2 translocated from the nucleus to the cytoplasm. However, we observed a decrease in HSP90, CK2, and Akt activity in ALS patients compared to NNDPs. A previous study reported that InsP<sub>6</sub>K2 activity is suppressed after binding to HSP90 and subsequent phosphorylation and degradation by CK2, thus decreasing InsP<sub>6</sub>K2 activity. However, InsP<sub>7</sub>, which is generated by InsP<sub>6</sub>K2, can compete with Akt for PH domain binding. Consequently, InsP<sub>7</sub> can inhibit Akt phosphorylation. Our results suggest that InsP<sub>6</sub>K2 is activated in the spinal cord of patients with ALS and may play an important role in ALS by inducing cell death mechanisms via Akt, CK2, and HSP90 pathways.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nagata</LastName><ForeName>Eiichiro</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6902-8309</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, Kanagawa, 259-1193, Japan. enagata@is.icc.u-tokai.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujii</LastName><ForeName>Natsuko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, Kanagawa, 259-1193, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohara</LastName><ForeName>Saori</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, Kanagawa, 259-1193, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okada</LastName><ForeName>Chisa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Support Center for Medical Research and Education, Tokai University, Isehara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satoh</LastName><ForeName>Tadayuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Support Center for Medical Research and Education, Tokai University, Isehara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takekoshi</LastName><ForeName>Susumu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Pathology, Tokai University School of Medicine, Isehara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takao</LastName><ForeName>Masaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, National Center of Neurology and Psychiatry (NCNP), National Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mihara</LastName><ForeName>Ban</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mihara Memorial Hospital, Gunma, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takizawa</LastName><ForeName>Shunya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, Kanagawa, 259-1193, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JP 19K07851</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country/></Grant><Grant><GrantID>16H06277</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Mol Biol Rep</MedlineTA><NlmUniqueID>0403234</NlmUniqueID><ISSNLinking>0301-4851</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018841">HSP90 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D047390">Casein Kinase II</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.4.-</RegistryNumber><NameOfSubstance UI="D017856">Phosphotransferases (Phosphate Group Acceptor)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.4.21</RegistryNumber><NameOfSubstance UI="C115134">IP6K1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000870" MajorTopicYN="N">Anterior Horn Cells</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047390" MajorTopicYN="N">Casein Kinase II</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018841" MajorTopicYN="N">HSP90 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017856" MajorTopicYN="N">Phosphotransferases (Phosphate Group Acceptor)</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070539" MajorTopicYN="N">Pleckstrin Homology Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Akt depletion</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Cell death</Keyword><Keyword MajorTopicYN="N">Inositol hexakisphosphate kinase 2</Keyword><Keyword MajorTopicYN="N">Spinal cord anterior horn cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>15</Day><Hour>5</Hour><Minute>49</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32929655</ArticleId><ArticleId IdType="doi">10.1007/s11033-020-05688-w</ArticleId><ArticleId IdType="pii">10.1007/s11033-020-05688-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Irvine RF, Schell MJ (2001) Back in the water: the return of the inositol phosphates. Nat Rev Mol Cell Biol 2:327&#x2013;338</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35073015</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick AC, Saiardi A (2008) Inositol polyphosphate multikinase: metabolic architect of nuclear inositides. Front Biosci 13:856&#x2013;866</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/2726</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikoshiba K, Furuichi T, Miyawaki A (1994) Structure and function of IP3 receptors. Semin Cell Biol 5:273&#x2013;281</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/scel.1994.1033</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikoshiba K (2007) IP<sub>3</sub> receptor/Ca<sup>2+</sup> channel: from discovery to new signaling concepts. J Neurochem 102:1426&#x2013;1446</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04825.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett M, Onnebo SM, Azevedo C, Saiardi A (2006) Inositol pyrophosphates: metabolism and signaling. Cell Mol Life Sci 63:552&#x2013;564</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-005-5446-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton A, Hu X, Saiardi A (2009) Are inositol pyrophosphates signalling molecules? J Cell Physiol 220:8&#x2013;15</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.21763</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo HR, Huang YE, Chen JC, Saiardi A, Iijima M, Ye K, Huang Y, Nagata E, Devreotes P, Snyder SH (2003) Inositol pyrophosphates mediate chemotaxis in Dictyostelium via pleckstrin homology domain-Ptdlns (3,4,5) P3 interactions. Cell 114:559&#x2013;572</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(03)00640-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Saiardi A, Sciambi C, McCaffery JM, Wendland B, Snyder SH (2002) Inositol pyrophosphates regulate endocytic trafficking. Proc Natl Acad Sci U S A 99:14206&#x2013;14211</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.212527899</ArticleId></ArticleIdList></Reference><Reference><Citation>Saiardi A, Bhandari R, Resnick AC, Snowman AM, Snyder SH (2004) Phosphorylation of proteins by inositol pyrophosphates. Science 306:2101&#x2013;2105</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1103344</ArticleId></ArticleIdList></Reference><Reference><Citation>Shears SB (2007) Understanding the biological significance of diphosphoinositol polyphosphates (&#x2018;inositol pyrophosphates&#x2019;). Biochem Soc Symp 74:211&#x2013;221</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSS2007c18</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison BH, Haney R, Lamarre E, Drazba J, Prestwich GD, Linder DJ (2009) Gene deletion of inositol hexakisphosphate kinase 2 predisposes to aerodigestive tract carcinoma. Oncogene 28:2383&#x2013;2392</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2009.113</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata E, Luo HR, Saiardi A, Bae BI, Suzuki N, Snyder SH (2005) Inositol hexakisphosphate kinase-2, a physiologic mediator of cell death. J Biol Chem 280:1634&#x2013;1640</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M409416200</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison BH, Bauer JA, Kalvakolanu DV, Lindner DJ (2001) Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-&#x3b2; in ovarian carcinoma cells. J Biol Chem 276:24965&#x2013;24970</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M101161200</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata E, Saiardi A, Tsukamoto H, Okada Y, Itoh Y, Satoh T, Itoh J, Margolis RL, Takizawa S, Sawa A, Takagi S (2011) Inositol hexakisphosphate kinases induce cell death in Huntington disease. J Biol Chem 286:26680&#x2013;26686</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.220749</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata E, Nonaka T, Moriya Y, Fujii N, Okada Y, Tsukamoto H, Itoh J, Okada C, Satoh T, Arai T, Hasegawa M, Takizawa S (2016) Inositol hexakisphosphate kinase 2 promotes cell death in cells with cytoplasmic TDP-43 aggregation. Mol Neurobiol 53:5377&#x2013;5383</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9470-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293&#x2013;299</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaffl MW (2006) Relative quantification. In: Dorak MT (ed) Real-time PCR. Taylor and Francis, New York, pp 63&#x2013;82</Citation></Reference><Reference><Citation>Nelson LM (1995) Epidemiology of ALS. Clin Neurosci 3:327&#x2013;331</Citation><ArticleIdList><ArticleId IdType="pubmed">9021253</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland DW, Rothstein JD (2001) From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2:806&#x2013;819</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35097565</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59&#x2013;62</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriya Y, Nagata E, Fujii N, Satoh T, Ogawa H, Hadano S, Takizawa S (2017) Inositol hexakisphosphate kinase 2 is a presymptomatic biomarker for amyotrophic lateral sclerosis. Tokai J Exp Clin Med 42:13&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pubmed">28413866</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii A, Nonaka T, Taniguchi S, Saito T, Arai T, Mann D, Iwatsubo T, Hisanaga S, Goedert M, Hasegawa M (2007) Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human &#x3b1;-synuclein: implication for &#x3b1;-synucleinopathies. FEBS Lett 581:4711&#x2013;4717</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2007.08.067</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty A, Werner JK Jr, Koldobskiy MA, Mustafa AK, Juluri KR, Pietropaoli J, Snowman AM, Snyder SH (2011) Casein kinase-2 mediates cell survival through phosphorylation and degradation of inositol hexakisphosphate kinase-2. Proc Natl Acad Sci U S A 108:2205&#x2013;2209</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1019381108</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F, Pinna M, Ruzzene M (2005) Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 12:668&#x2013;677</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4401604</ArticleId></ArticleIdList></Reference><Reference><Citation>Song DH, Dominguez I, Mizuno J, Kaut M, Mohr SC, Seldin DC (2003) CK2 phosphorylation of the armadillo repeat region of &#x3b2;-catenin potentiates Wnt signaling. J Biol Chem 278:24018&#x2013;24025</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M212260200</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761&#x2013;772</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc1716</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Bansal A, Hashimoto-Torii K (2020) HSP70 and HSP90 in neurodegenerative diseases. Neurosci Lett 716:134678</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2019.134678</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp S, Workman P (2006) Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 95:323&#x2013;348</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0065-230X(06)95009-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Maloney A, Workman P (2002) HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2:3&#x2013;24</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2.1.3</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Gendron TF, Xu YF, Ko LW, Yen SH, Petrucelli L (2010) Phosphorylation regulates proteasomal-mediated degradation and solubility of TAR DNA binding protein-43 C-terminal fragments. Mol Neurodegener 5:33</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-5-33</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty A, Koldobskiy MA, Sixt K, Juluri KR, Mustafa AK, Snowman A, van Rossum DB, Patterson RL, Snyder SH (2008) HSP90 regulates cell survival via inositol hexakisphosphate kinase-2. Proc Natl Acad Sci U S A 105:1134&#x2013;1139</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0711168105</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty A, Koldobskiy MA, Bello NT, Maxwell M, Potter JJ, Juluri KR, Maag D, Kim S, Huang AS, Dailey MJ, Saleh M, Snowman AM, Moran TH, Mezey E, Snyder SH (2010) Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain. Cell 143:897&#x2013;910</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.11.032</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>